Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB announced that its board and executive management have entered into lock-up agreements for their shares, which account for 6.9% of the company’s votes and capital, until December 31, 2025. This move underscores the leadership’s commitment to the company’s future development and stability, potentially reassuring stakeholders about the company’s strategic direction and long-term goals.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases.
Average Trading Volume: 230,376
Current Market Cap: SEK944.6M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.